Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the French version of its 2016 Reference document was filed with the Autorités des Marchés Financiers (AMF)...

Increased scope to explore additional cohorts of Opdivo (nivolumab) plus lirilumab in solid tumors, including a cohort exploring Opdivo with or without lirilumab in squamous cell carcinoma of the head...

Cash, cash equivalents and financial instruments* amounted to €230.7m (million euros) as of December 31, 2016 Revenue and other income amounted to €65.7m (€25.1m in 2015), including $15m (€13.8m)...

Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces...

The study did not meet the primary efficacy endpoint Study confirms the safety profile of lirilumab as a monotherapy Broad clinical program ongoing, investigating lirilumab in a variety of tumor...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that, per the licensing agreement for lirilumab, Bristol-Myers Squibb has paid Innate Pharma a US$15 million...

Preliminary data from the dose-escalation part of an ongoing Phase I trial in elderly and heavily pretreated patients including a majority of patients with Sezary syndrome; IPH4102 shows good safety...

Cash, cash equivalents and financial assets amounting to €239.6 million [1] Continued progress with key clinical trials Safety data for lirilumab in combination in Phase I studies presented at the...

Abstract now available online - More data in oral presentation on November 12 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces the publication of the late-breaking...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the Company will host a conference call for institutional investors and sell-side analysts to discuss recent...